By Marie Rosenthal
BOSTON—A potential new antiretroviral therapy doravirine (Merck), a late-stage investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), was found to be effective and well tolerated, according to a presentation at CROI 2018.
Researchers also presented data on another Merck pipeline candidate, MK-8591, an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI).
“Doravirine is a novel, next-generation NNRTI, which has properties